TGN1412: From Discovery to Disaster
Open Access
- 1 July 2010
- journal article
- Published by EManuscript Technologies in Journal of Young Pharmacists
- Vol. 2 (3), 332-336
- https://doi.org/10.4103/0975-1483.66810
Abstract
After a drug is confirmed as safe and efficacious in preclinical studies, it is tested in healthy human volunteers for first in man trials. In 2006, a phase I clinical study was conducted for a CD28 superagonist antibody TGN1412 in six human volunteers. After very first infusion of a dose 500 times smaller than that found safe in animal studies, all six human volunteers faced life-threatening conditions involving multiorgan failure for which they were moved to intensive care unit. After this particular incident, a lot was changed over how first in man trials are approved by regulatory authorities and the way clinical trials are conducted. This review primarily deals with preclinical studies conducted by TeGenero, results of which encouraged them to test the antibody on human subjects, reasons why this drug failed in human trial and aftermath of this drug trial. In addition, another drug—Fialuridine which failed in phase 2 clinical trial leading to death of five human subjects is briefly reviewed.Keywords
This publication has 20 references indexed in Scilit:
- The TeGenero Incident and the Duff Report Conclusions: A Series of Unfortunate Events or an Avoidable Event?Toxicologic Pathology, 2009
- CD28 Superagonists: What Makes the Difference in Humans?Immunity, 2008
- Preparing for first-in-man studies: the challenges for translational immunology post-TGN1412Clinical and Experimental Immunology, 2008
- Review of Sofia Gruskin, Michael A. Grodin, George J. Annas, and Stephen P. Marks (eds.),Perspectives on Health and Human Rights. Oxford, UK: Routledge, 2005. 672 pp. $36.95, paperbackAmerican Journal of Bioethics, 2007
- Ethical Flaws in the TeGenero TrialAmerican Journal of Bioethics, 2007
- Further lessons from the TGN1412 tragedyBMJ, 2006
- Phase I Antibody Risks, Trial Safety ExaminedJNCI Journal of the National Cancer Institute, 2006
- TGN1412: scrutinizing preclinical trials of antibody-based medicinesNature, 2006
- Allergy test might have avoided drug-trial disasterNature, 2006
- Mitochondrial Injury Lessons from the Fialuridine TrialDrug Safety, 1997